Pluripotent stem cell-derived chimeric antigen receptor-natural killer cells targeting epidermal growth factor receptor 2 for cancer immunotherapy

Chimeric antigen receptor-natural killer (CAR-NK) cells are emerging as a promising platform for allogeneic, cell-based immunotherapy. Among available sources, NK cells derived from pluripotent stem cells (PSCs) provide a renewable and scalable option that overcomes the limitations of primary NK cel...

Full description

Saved in:
Bibliographic Details
Published in:BMB reports Vol. 58; no. 11; p. 475
Main Authors: Han, Jongsuk, Jin, Chaeyeon, Hwang, Sae-Byeok, Lee, In Jee, Baek, Young Seok, Jung, Daun, Kim, Ki Yeon, Mitalipov, Shoukhrat, Kim, Ji Hyang, An, Hee Jung, Lee, Yeonmi, Kang, Eunju
Format: Journal Article
Language:English
Published: Korea (South) 01.11.2025
Subjects:
ISSN:1976-670X, 1976-670X
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Chimeric antigen receptor-natural killer (CAR-NK) cells are emerging as a promising platform for allogeneic, cell-based immunotherapy. Among available sources, NK cells derived from pluripotent stem cells (PSCs) provide a renewable and scalable option that overcomes the limitations of primary NK cells. Human epidermal growth factor receptor 2 (HER2), a membrane protein frequently overexpressed in many solid tumors, is an attractive target for cancer immunotherapy. In this study, we designed a green fluorescent protein (GFP)-linked anti-HER2 CAR construct and introduced it into PSCs via lentiviral transduction. Three stable PSC-derived clones (CAR-A, CAR-B, and CAR-C) were established, each co-expressing anti-HER2 CAR with GFP. After differentiation under xeno-free and feeder-free culture conditions, CAR expression was maintained in NK cells. The resulting PSC-derived CAR-NK cells displayed phenotypic and functional features comparable to wild-type PSC-derived NK cells, while showing markedly enhanced cytotoxicity against HER2-positive cancer cell lines. These findings demonstrated the potential of the use of PSC-derived anti-HER2 CAR-NK cells as a robust and scalable immunotherapy. In addition, this platform could be extended to produce CAR-NK cells directed against a wide range of tumorassociated antigens. [BMB Reports 2025; 58(11): 475-483].
AbstractList Chimeric antigen receptor-natural killer (CAR-NK) cells are emerging as a promising platform for allogeneic, cell-based immunotherapy. Among available sources, NK cells derived from pluripotent stem cells (PSCs) provide a renewable and scalable option that overcomes the limitations of primary NK cells. Human epidermal growth factor receptor 2 (HER2), a membrane protein frequently overexpressed in many solid tumors, is an attractive target for cancer immunotherapy. In this study, we designed a green fluorescent protein (GFP)-linked anti-HER2 CAR construct and introduced it into PSCs via lentiviral transduction. Three stable PSC-derived clones (CAR-A, CAR-B, and CAR-C) were established, each co-expressing anti-HER2 CAR with GFP. After differentiation under xeno-free and feeder-free culture conditions, CAR expression was maintained in NK cells. The resulting PSC-derived CAR-NK cells displayed phenotypic and functional features comparable to wild-type PSC-derived NK cells, while showing markedly enhanced cytotoxicity against HER2-positive cancer cell lines. These findings demonstrated the potential of the use of PSC-derived anti-HER2 CAR-NK cells as a robust and scalable immunotherapy. In addition, this platform could be extended to produce CAR-NK cells directed against a wide range of tumorassociated antigens. [BMB Reports 2025; 58(11): 475-483].
Chimeric antigen receptor-natural killer (CAR-NK) cells are emerging as a promising platform for allogeneic, cell-based immunotherapy. Among available sources, NK cells derived from pluripotent stem cells (PSCs) provide a renewable and scalable option that overcomes the limitations of primary NK cells. Human epidermal growth factor receptor 2 (HER2), a membrane protein frequently overexpressed in many solid tumors, is an attractive target for cancer immunotherapy. In this study, we designed a green fluorescent protein (GFP)-linked anti-HER2 CAR construct and introduced it into PSCs via lentiviral transduction. Three stable PSC-derived clones (CAR-A, CAR-B, and CAR-C) were established, each co-expressing anti-HER2 CAR with GFP. After differentiation under xeno-free and feeder-free culture conditions, CAR expression was maintained in NK cells. The resulting PSC-derived CAR-NK cells displayed phenotypic and functional features comparable to wild-type PSC-derived NK cells, while showing markedly enhanced cytotoxicity against HER2-positive cancer cell lines. These findings demonstrated the potential of the use of PSC-derived anti-HER2 CAR-NK cells as a robust and scalable immunotherapy. In addition, this platform could be extended to produce CAR-NK cells directed against a wide range of tumor-associated antigens.Chimeric antigen receptor-natural killer (CAR-NK) cells are emerging as a promising platform for allogeneic, cell-based immunotherapy. Among available sources, NK cells derived from pluripotent stem cells (PSCs) provide a renewable and scalable option that overcomes the limitations of primary NK cells. Human epidermal growth factor receptor 2 (HER2), a membrane protein frequently overexpressed in many solid tumors, is an attractive target for cancer immunotherapy. In this study, we designed a green fluorescent protein (GFP)-linked anti-HER2 CAR construct and introduced it into PSCs via lentiviral transduction. Three stable PSC-derived clones (CAR-A, CAR-B, and CAR-C) were established, each co-expressing anti-HER2 CAR with GFP. After differentiation under xeno-free and feeder-free culture conditions, CAR expression was maintained in NK cells. The resulting PSC-derived CAR-NK cells displayed phenotypic and functional features comparable to wild-type PSC-derived NK cells, while showing markedly enhanced cytotoxicity against HER2-positive cancer cell lines. These findings demonstrated the potential of the use of PSC-derived anti-HER2 CAR-NK cells as a robust and scalable immunotherapy. In addition, this platform could be extended to produce CAR-NK cells directed against a wide range of tumor-associated antigens.
Author Jung, Daun
Kang, Eunju
Jin, Chaeyeon
Baek, Young Seok
Lee, In Jee
Kim, Ji Hyang
Hwang, Sae-Byeok
Mitalipov, Shoukhrat
Han, Jongsuk
Kim, Ki Yeon
An, Hee Jung
Lee, Yeonmi
Author_xml – sequence: 1
  givenname: Jongsuk
  surname: Han
  fullname: Han, Jongsuk
  organization: Department of Biomedical Science, College of Life Science, CHA University, Seongnam 13488, Korea
– sequence: 2
  givenname: Chaeyeon
  surname: Jin
  fullname: Jin, Chaeyeon
  organization: Department of Biomedical Science, College of Life Science, CHA University, Seongnam 13488, Korea
– sequence: 3
  givenname: Sae-Byeok
  surname: Hwang
  fullname: Hwang, Sae-Byeok
  organization: Department of Biomaterials Engineering, School of Medicine, and Biomedical Science, College of Life Science, CHA University, Seongnam 13488; CHA Medical Research Institute, CHA Bundang Medical Center, Seongnam 13488, Korea
– sequence: 4
  givenname: In Jee
  surname: Lee
  fullname: Lee, In Jee
  organization: Department of Biomaterials Engineering, School of Medicine, and Biomedical Science, College of Life Science, CHA University, Seongnam 13488, Korea
– sequence: 5
  givenname: Young Seok
  surname: Baek
  fullname: Baek, Young Seok
  organization: Department of Biomaterials Engineering, School of Medicine, and Biomedical Science, College of Life Science, CHA University, Seongnam 13488, Korea
– sequence: 6
  givenname: Daun
  surname: Jung
  fullname: Jung, Daun
  organization: Department of Pathology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13496, Korea
– sequence: 7
  givenname: Ki Yeon
  surname: Kim
  fullname: Kim, Ki Yeon
  organization: Department of Pathology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13496, Korea
– sequence: 8
  givenname: Shoukhrat
  surname: Mitalipov
  fullname: Mitalipov, Shoukhrat
  organization: Center for Embryonic Cell and Gene Therapy, Oregon Health and Science University, Portland, OR 97239, USA
– sequence: 9
  givenname: Ji Hyang
  surname: Kim
  fullname: Kim, Ji Hyang
  organization: Department of Obstetrics and Gynecology, CHA Bundang Medical Center, School of Medicine, CHA University, Seongnam 13496, Korea
– sequence: 10
  givenname: Hee Jung
  surname: An
  fullname: An, Hee Jung
  organization: Department of Pathology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13496, Korea
– sequence: 11
  givenname: Yeonmi
  surname: Lee
  fullname: Lee, Yeonmi
  organization: CHA Medical Research Institute, CHA Bundang Medical Center, Seongnam 13488, Korea
– sequence: 12
  givenname: Eunju
  surname: Kang
  fullname: Kang, Eunju
  organization: Department of Biomedical Science, College of Life Science, CHA University, Seongnam 13488; CHA Medical Research Institute, CHA Bundang Medical Center, Seongnam 13488; Department of Biochemistry, School of Medicine, CHA University, Seongnam 13488, Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/41168893$$D View this record in MEDLINE/PubMed
BookMark eNpNkDtPwzAUhS1UREvpzoQ8sqQkcRKnI6p4SZVgAIkt8uM6tYidYDug_g1-MQYKYrn3DOc70jnHaGJ7CwidZumyLGpywQ13MCzzNC-TNCP0AM2yFa2SiqbPk396ihbea56WhNCK1qsjNC2yrKrrFZmhj4dudHroA9iAfQCDBXRdIsHpN5BYbLWJUmBmg27BYgcChtC7xLIwOtbhF9114L4pjwNzLQRtWwyDjhkmGlrXv4ctVkxE7I_HOVbxCmZFpLUxo-3DFhwbdifoULHOw2L_5-jp-upxfZts7m_u1pebxGaxSUIYzyiTSnKhgHBVljUA47IQaU0lA1mnPBe0kopTqigjuSzKWpKSR82Uyufo_Cd3cP3rCD40RvuvHsxCP_qG5BUtsqJc0Wg921tHbkA2g9OGuV3zu2P-CXBqfuY
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.5483/bmbrep.2025-0137
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
EISSN 1976-670X
ExternalDocumentID 41168893
Genre Journal Article
News
GroupedDBID .UV
ALMA_UNASSIGNED_HOLDINGS
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-n1337-3ab17adfdbcfe3bf558eeabd4c087daed80b2c76dfb77f7a32d458d35b7a3aff2
IEDL.DBID 7X8
ISSN 1976-670X
IngestDate Sat Nov 01 12:11:19 EDT 2025
Thu Nov 27 01:51:57 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-n1337-3ab17adfdbcfe3bf558eeabd4c087daed80b2c76dfb77f7a32d458d35b7a3aff2
Notes content type line 23
SourceType-Scholarly Journals-1
ObjectType-News-1
OpenAccessLink https://www.bmbreports.org/journal/download_pdf.php?doi=10.5483/BMBRep.2025-0137
PMID 41168893
PQID 3267414597
PQPubID 23479
ParticipantIDs proquest_miscellaneous_3267414597
pubmed_primary_41168893
PublicationCentury 2000
PublicationDate 2025-Nov
PublicationDateYYYYMMDD 2025-11-01
PublicationDate_xml – month: 11
  year: 2025
  text: 2025-Nov
PublicationDecade 2020
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle BMB reports
PublicationTitleAlternate BMB Rep
PublicationYear 2025
SSID ssib053376789
Score 2.420599
Snippet Chimeric antigen receptor-natural killer (CAR-NK) cells are emerging as a promising platform for allogeneic, cell-based immunotherapy. Among available sources,...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 475
SubjectTerms Cell Differentiation
Cell Line, Tumor
Humans
Immunotherapy - methods
Immunotherapy, Adoptive - methods
Killer Cells, Natural - cytology
Killer Cells, Natural - immunology
Killer Cells, Natural - metabolism
Neoplasms - immunology
Neoplasms - therapy
Pluripotent Stem Cells - cytology
Pluripotent Stem Cells - immunology
Pluripotent Stem Cells - metabolism
Receptor, ErbB-2 - immunology
Receptor, ErbB-2 - metabolism
Receptors, Chimeric Antigen - immunology
Receptors, Chimeric Antigen - metabolism
Title Pluripotent stem cell-derived chimeric antigen receptor-natural killer cells targeting epidermal growth factor receptor 2 for cancer immunotherapy
URI https://www.ncbi.nlm.nih.gov/pubmed/41168893
https://www.proquest.com/docview/3267414597
Volume 58
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS8MwFA7qfPDFC97mjQi-hq1J27RPMuamIpaBE_o2kiZhg62bWzfwb_iLPUm7-SQIvpS-HCjJ1-98JyfnHITuFFUZFT4lKmQh8amgRPoiJlIpDwjRREyXwyZ4kkRpGveqA7dFda1yzYmOqNU0s2fkDZAZ4Px80L_3sw9ip0bZ7Go1QmMb1RhIGYtqnm7wBEqGAxfHLrHMQxLyZlpmKkGms4acQNBpW1ZSe32N8d81pvM13YP_fuUh2q9UJm6VsDhCWzo_Rl-98RIoYgoqucBvhZ7gth6PyQNgcKUVbg9HLnuDW3lhW3RiUJR6BiE5SYRrzoFfXN2gs1rgvrtCDo4Pd-yQWeD3MX6EmL4Y4q6b4bOxxxSDMsZti685frYFKVXZ1-cJeu92-u0nUo1kIDkEs0BHQnpcKKNkZjSTJggirYVUftaMuBJaRU1JMx4qIzk3XDCq_CBSLJDwLoyhp2gnn-b6HGEr1UDLBMww5nMTy1hnEI4Lmzr0Ah3U0e16iQcAeZvHELmeLheDn0Wuo7NynwazsjfHwPe8MAINdvEH60u05zbfVRZeoZqBH15fo91sVYwW8xuHJXgmvddv0E7X6Q
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pluripotent+stem+cell-derived+chimeric+antigen+receptor-natural+killer+cells+targeting+epidermal+growth+factor+receptor+2+for+cancer+immunotherapy&rft.jtitle=BMB+reports&rft.au=Han%2C+Jongsuk&rft.au=Jin%2C+Chaeyeon&rft.au=Hwang%2C+Sae-Byeok&rft.au=Lee%2C+In+Jee&rft.date=2025-11-01&rft.eissn=1976-670X&rft.volume=58&rft.issue=11&rft.spage=475&rft_id=info:doi/10.5483%2Fbmbrep.2025-0137&rft_id=info%3Apmid%2F41168893&rft_id=info%3Apmid%2F41168893&rft.externalDocID=41168893
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1976-670X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1976-670X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1976-670X&client=summon